Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2012, Article ID 784364, 13 pages
http://dx.doi.org/10.1155/2012/784364
Review Article

Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature

1Department of Health Systems, Management, and Policy, Colorado School of Public Health, 13001 E 17th Place, Aurora, CO 80045, USA
2Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA

Received 10 August 2012; Accepted 31 October 2012

Academic Editor: Giovanni Savettieri

Copyright © 2012 David Yamamoto and Jonathan D. Campbell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. D. Goldberg, N. C. Edwards, C. Fincher, Q. V. Doan, A. Al-Sabbagh, and D. M. Meletiche, “Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis,” Journal of Managed Care Pharmacy, vol. 15, no. 7, pp. 543–555, 2009. View at Google Scholar · View at Scopus
  2. H. L. Zwibel and J. Smrtka, “Improving quality of life in multiple sclerosis: an unmet need,” The American Journal of Managed Care, vol. 17, supplement 5, pp. S139–S145, 2011. View at Google Scholar
  3. C. J. Phillips, “The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment,” CNS Drugs, vol. 18, no. 9, pp. 561–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Olofsson, A. Wickstrom, A. Hager Glenngard, U. Persson, and A. Svenningsson, “Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment,” BioDrugs, vol. 25, no. 5, pp. 299–306, 2011. View at Google Scholar
  5. Multiple Sclerosis Association of America, Treatments for Multiple Sclerosis, 2012, http://www.msassociation.org/about_multiple_sclerosis/treating/.
  6. J. A. Schafer, B. W. Gunderson, and P. P. Gleason, “Price increases and new drugs drive increased expenditures for multiple sclerosis,” Journal of Managed Care Pharmacy, vol. 16, no. 9, pp. 713–717, 2010. View at Google Scholar · View at Scopus
  7. G. Kobelt, P. Lindgren, A. Smala et al., “Costs and quality of life in multiple sclerosis. An observational study in Germany,” HEPAC Health Economics in Prevention and Care, vol. 2, no. 2, pp. 60–68, 2001. View at Google Scholar · View at Scopus
  8. G. Kobelt, P. Lindgren, D. Parkin et al., “Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the United Kingdom,” EFI Research Reports, Stockholm, Sweden, 2000. View at Google Scholar
  9. F. Henriksson, S. Fredrikson, T. Masterman, and B. Jönsson, “Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden,” European Journal of Neurology, vol. 8, no. 1, pp. 27–35, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. T. Grima, G. W. Torrance, G. Francis, G. Rice, A. J. Rosner, and L. Lafortune, “Cost and health related quality of life consequences of multiple sclerosis,” Multiple Sclerosis, vol. 6, no. 2, pp. 91–98, 2000. View at Google Scholar · View at Scopus
  11. G. Kobelt, J. Berg, D. Atherly, and O. Hadjimichael, “Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States,” Neurology, vol. 66, no. 11, pp. 1696–1702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Russo, A. Capone, A. Paolillo et al., “Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents,” Clinical Drug Investigation, vol. 24, no. 7, pp. 409–420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. P. D. R. Staff Thomson, Red Book: Pharmacy's Fundamental Reference, Thomson Healthcare, 114th edition, 2010.
  14. Gilenya (fingolimod) [package insert], East Hanover, NJ, USA, Novartis, 2010.
  15. B. H. Pharmaceuticals, “Betaseron Prescribing Information,” 2012, http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf.
  16. I. Biogen, “Avonex Prescribing Information,” 2012, http://www.avonex.com/pdfs/guides/Avonex_Prescribing_Information.pdf.
  17. I. Teva Neuroscience, “Copaxone Prescribing Information,” 2010, http://www.sharedsolutions.com/redirect/PrescribingInformation.pdf.
  18. National Center for Biotechnology Information, “Novantrone Black Box Warning,” 2010, http://www.ncbi.nlm.nih.gov/books/NBK50576/.
  19. E. M. D. Serono I, “Rebif Prescribing Information,” 2012, http://www.emdserono.com/cmg.emdserono_us/en/images/rebif_tcm115_19765.pdf.
  20. I. Elan Pharmaceuticals, “Tysabri Prescriber Information,” 2012, http://www.tysabri.com/pdfs/I61061-13_PI.pdf.
  21. N. P. Corporation, “Extavia Important Product Information (Prescribing Information),” 2012, http://www.pharma.us.novartis.com/product/pi/pdf/extavia.pdf.
  22. N. P. Coporation, “Gilenya Prescribing Information,” 2012, http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf.
  23. M. P. Amato, “Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents,” Expert Opinion on Pharmacotherapy, vol. 5, no. 10, pp. 2115–2126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Flachenecker and P. Rieckmann, “Early intervention in multiple sclerosis: better outcomes for patients and society?” Drugs, vol. 63, no. 15, pp. 1525–1533, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Flachenecker and P. Rieckmann, “Health outcomes in multiple sclerosis,” Current Opinion in Neurology, vol. 17, no. 3, pp. 257–261, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Kobelt, “Health economic issues in MS,” International MS Journal / MS Forum, vol. 13, no. 1, pp. 16–17, 2006. View at Google Scholar · View at Scopus
  27. P. Rieckmann, “Socio-economic aspects of neuroimmunological diseases,” Journal of Neurology, vol. 253, no. 5, pp. V 87–V 90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Drummond Michael SMJ, W. Torrance George, J. O.'Brien Bernie, and L. Stoddart Greg, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, New York, NY, USA, 3rd edition, 2005.
  29. F. Sloan, Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, Cambridge University Press, Cambridge, UK, USA, 1996.
  30. J. D. Campbell, D. E. Spackman, and S. D. Sullivan, “Health economics of asthma: assessing the value of asthma interventions,” Allergy, vol. 63, no. 12, pp. 1581–1592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Philips, L. Bojke, M. Sculpher, K. Claxton, and S. Golder, “Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment,” PharmacoEconomics, vol. 24, no. 4, pp. 355–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. F. Chiou, J. W. Hay, J. F. Wallace et al., “Development and validation of a grading system for the quality of cost-effectiveness studies,” Medical Care, vol. 41, no. 1, pp. 32–44, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Bakhshai, R. Bleu-Lainé, M. Jung et al., “The cost effectiveness and budget impact of natalizumab for formulary inclusion,” Journal of Medical Economics, vol. 13, no. 1, pp. 63–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. R. V. Becker III and C. Dembek, “Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis,” Journal of Managed Care Pharmacy, vol. 17, no. 5, pp. 377–381, 2011. View at Google Scholar
  35. C. Bell, J. Graham, S. Earnshaw, M. Oleen-Burkey, J. Castelli-Haley, and K. Johnson, “Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data,” Journal of Managed Care Pharmacy, vol. 13, no. 3, pp. 245–261, 2007. View at Google Scholar · View at Scopus
  36. M. Boggild, J. Palace, P. Barton et al., “Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator,” British Medical Journal, vol. 339, p. b4677, 2009. View at Google Scholar · View at Scopus
  37. M. G. Brown, T. Jock Murray, I. S. Sketris et al., “Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates,” International Journal of Technology Assessment in Health Care, vol. 16, no. 3, pp. 751–767, 2000. View at Google Scholar · View at Scopus
  38. J. Castelli-Haley, M. A. Oleen-Burkey, M. J. Lage, and K. P. Johnson, “Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis,” Advances in Therapy, vol. 26, no. 5, pp. 552–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Chiao and K. Meyer, “Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis,” Current Medical Research and Opinion, vol. 25, no. 6, pp. 1445–1454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Chilcott, C. McCabe, P. Tappenden et al., “Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis,” British Medical Journal, vol. 326, no. 7388, pp. 522–525, 2003. View at Google Scholar · View at Scopus
  41. A. Clegg and J. Bryant, “Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness,” Expert Opinion on Pharmacotherapy, vol. 2, no. 4, pp. 623–639, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Clegg, J. Bryant, and R. Milne, “Disease-modifying drugs for multiple sclerosis: a rapid and systematic review,” Health Technology Assessment, vol. 4, no. 9, pp. 1–101, 2000. View at Google Scholar · View at Scopus
  43. A. Coles, “The fragile benefit of BENEFIT,” Lancet Neurology, vol. 6, no. 9, pp. 753–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Compston, “Commentary: scheme has benefited patients,” British Medical Journal, vol. 340, p. c2707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. F. R. Curtiss, “Pharmacoeconomic modeling of drug therapies for multiple sclerosis—are we building houses on sand?” Journal of Managed Care Pharmacy, vol. 13, no. 3, pp. 287–289, 2007. View at Google Scholar · View at Scopus
  46. B. Detournay, “The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis,” Value in Health, vol. 5, no. 1, pp. 1–2, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Devlin, J. Appleby, and D. Parkin, “Patients' views of explicit rationing: what are the implications for health service decision-making?” Journal of Health Services Research and Policy, vol. 8, no. 3, pp. 183–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. S. R. Earnshaw, J. Graham, M. Oleen-Burkey, J. Castelli-Haley, and K. Johnson, “Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis,” Applied Health Economics and Health Policy, vol. 7, no. 2, pp. 91–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. G. C. Ebers, “Commentary: outcome measures were flawed,” British Medical Journal, vol. 340, p. c2693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. J. Ellis, “Bad decision NICE,” The Lancet, vol. 359, no. 9304, p. 447, 2002. View at Google Scholar · View at Scopus
  51. R. B. Forbes, A. Lees, N. Waugh, and R. J. Swingler, “Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis,” British Medical Journal, vol. 319, no. 7224, pp. 1529–1533, 1999. View at Google Scholar · View at Scopus
  52. R. Gani, G. Giovannoni, D. Bates, B. Kemball, S. Hughes, and J. Kerrigan, “Cost-effectiveness analyses of natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK,” PharmacoEconomics, vol. 26, no. 7, pp. 617–627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. E. Gonsette, “A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 4, pp. 747–765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Greenhalgh, H. Ford, A. F. Long, and K. Hurst, “The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 4, pp. 577–582, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Guo, D. Bozkaya, A. Ward et al., “Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications,” PharmacoEconomics, vol. 27, no. 1, pp. 39–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. G. Heller, “Will public health survive QALYs?” Canadian Journal of Clinical Pharmacology, vol. 9, no. 1, pp. 5–6, 2002. View at Google Scholar · View at Scopus
  57. R. M. Herndon and L. Jacobs, “Interferons should be used to treat most patients with MS,” Archives of Neurology, vol. 55, no. 12, pp. 1581–1583, 1998. View at Google Scholar
  58. M. Iskedjian, J. H. Walker, T. Gray, C. Vicente, T. R. Einarson, and A. Gehshan, “Economic evaluation of Avonex (interferon beta-la) in patients following a single demyelinating event,” Multiple Sclerosis, vol. 11, no. 5, pp. 542–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. M. Jankovic, M. Kostic, M. Radosavljevic et al., “Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition,” Vojnosanitetski Pregled, vol. 66, no. 7, pp. 556–562, 2009. View at Google Scholar · View at Scopus
  60. K. P. Johnson and D. L. Due, “Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 9, no. 3, pp. 205–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Kendrick and K. I. Johnson, “Long term treatment of multiple sclerosis with interferon-β may be cost effective,” PharmacoEconomics, vol. 18, no. 1, pp. 45–53, 2000. View at Google Scholar · View at Scopus
  62. G. Kobelt, J. Berg, P. Lindgren, B. Jonsson, L. Stawiarz, and J. Hillert, “Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden,” Multiple Sclerosis, vol. 14, no. 5, pp. 679–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Kobelt, L. Jönsson, F. Henriksson, S. Fredrikson, and B. Jönsson, “Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis,” International Journal of Technology Assessment in Health Care, vol. 16, no. 3, pp. 768–780, 2000. View at Google Scholar · View at Scopus
  64. G. Kobelt, L. Jönsson, C. Miltenburger, and B. Jönsson, “Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data,” International Journal of Technology Assessment in Health Care, vol. 18, no. 1, pp. 127–138, 2002. View at Google Scholar · View at Scopus
  65. M. Lapé Nixon, J. Matud, C. Yeh, and H. E. Prince, “Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta,” Journal of Neuroimmunology, vol. 210, no. 1-2, pp. 104–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Lazzaro, C. Bianchi, L. Peracino, P. Zacchetti, and A. Uccelli, “Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b,” Neurological Sciences, vol. 30, no. 1, pp. 21–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. R. K. Lie, “Research ethics and evidence based medicine,” Journal of Medical Ethics, vol. 30, no. 2, pp. 122–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. R. MacDonald, “Cost effectiveness of multiple sclerosis drugs remains unknown,” British Medical Journal, vol. 321, no. 7258, p. 399, 2000. View at Google Scholar · View at Scopus
  69. C. McCabe, J. Chilcott, K. Claxton et al., “Continuing the multiple sclerosis risk sharing scheme is unjustified,” British Medical Journal, vol. 340, p. c1786, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. L. McKee, “Interferon beta produces only small benefits in multiple sclerosis,” British Medical Journal, vol. 316, no. 7142, p. 1410, 1998. View at Google Scholar · View at Scopus
  71. P. McNamee, “What difference does it make? The calculation of QALY gains from health profiles using patient and general population values,” Health Policy, vol. 84, no. 2-3, pp. 321–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. H. McNaughton, N. Kayes, and K. McPherson, “Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?” New Zealand Medical Journal, vol. 119, no. 1232, p. U1939, 2006. View at Google Scholar · View at Scopus
  73. F. Medina-Redondo, J. Herrera-Carranza, C. Sanabria et al., “The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia,” Revista de Neurologia, vol. 39, no. 1, pp. 1–6, 2004. View at Google Scholar · View at Scopus
  74. C. M. Meyer, R. Phipps, D. Cooper, and A. Wright, “Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data,” Journal of Managed Care Pharmacy, vol. 9, no. 2, pp. 168–174, 2003. View at Google Scholar · View at Scopus
  75. D. Murdoch and K. A. Lyseng-Williamson, “Subcutaneous recombinant interferon-β-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis,” Drugs, vol. 65, no. 9, pp. 1295–1312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. J. C. Napier, R. Francis, and G. Wright, “Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis,” British Medical Journal, vol. 326, no. 7400, p. 1212, 2003. View at Google Scholar · View at Scopus
  77. K. Noyes, A. Bajorska, A. Chappel et al., “Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study,” Neurology, vol. 77, no. 4, pp. 355–363, 2011. View at Google Scholar
  78. M. Nuijten and T. Mittendorf, “A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective,” Clinical Therapeutics, vol. 32, no. 4, pp. 717–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. M. J. C. Nuijten and J. Hutton, “Cost-effectiveness analysis of interferon beta in multiple sclerosis: a markov process analysis,” Value in Health, vol. 5, no. 1, pp. 44–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. K. O' Day, K. Meyer, R. M. Miller, S. Agarwal, and M. Franklin, “Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis,” Journal of Medical Economics, vol. 14, no. 5, pp. 617–627, 2011. View at Google Scholar
  81. D. Parkin, A. Jacoby, P. McNamee, P. Miller, S. Thomas, and D. Bates, “Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 2, pp. 144–149, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Parkin, P. McNamee, A. Jacoby, P. Miller, S. Thomas, and D. Bates, “A cost-utility analysis of interferon beta for multiple sclerosis,” Health Technology Assessment, vol. 2, no. 4, pp. 3–54, 1998. View at Google Scholar · View at Scopus
  83. M. Pickin, C. L. Cooper, T. Chater et al., “The multiple sclerosis risk sharing scheme monitoring study—early results and lessons for the future,” BMC Neurology, vol. 9, article 1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. L. A. Prosser, K. M. Kuntz, A. Bar-Or, and M. C. Weinstein, “Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis,” Value in Health, vol. 7, no. 5, pp. 554–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. W. Pryse-Phillips, “Newer long-term treatments for multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 104, no. 3, pp. 265–271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Raftery, “Multiple sclerosis risk sharing scheme: a costly failure,” BMBritish Medical Journal, vol. 340, p. c1672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. N. Rawson, “Response to McNaughton and colleagues regarding their article–interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?” The New Zealand Medical Journal, vol. 119, no. 1235, p. U2018, 2006. View at Google Scholar · View at Scopus
  88. M. W. Reynolds, R. Stephen, C. Seaman, and K. Rajagopalan, “Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs,” Journal of Medical Economics, vol. 13, no. 1, pp. 90–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. S. J. Rich and C. Meyer, “Shortcomings in pharmacy benefit forecasting–interferon beta products,” Journal of Managed Care Pharmacy, vol. 9, no. 4, pp. 373–374, 2003. View at Google Scholar · View at Scopus
  90. R. G. Richards, “Interferon beta in multiple sclerosis,” British Medical Journal, vol. 313, no. 7066, p. 1159, 1996. View at Google Scholar · View at Scopus
  91. R. G. Richards, “MS risk sharing scheme. Some clarification needed,” British Medical Journal, vol. 341, p. c3589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Rieckmann, “Early multiple sclerosis therapy in the effects of public health economics,” Medizinische Klinik, vol. 96, supplement 1, pp. 17–21, 2001. View at Google Scholar · View at Scopus
  93. P. Rieckmann and K. V. Toyka, “Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002,” Nervenarzt, vol. 73, no. 6, pp. 556–563, 2002. View at Google Scholar
  94. C. Rubio-Terrés, I. Arístegui Ruiz, F. Medina Redondo, and G. Izquierdo Ayuso, “Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain,” Farmacia Hospitalaria, vol. 27, no. 3, pp. 159–165, 2003. View at Google Scholar · View at Scopus
  95. C. Rubio-Terres and A. Dominguez-Gil Hurle, “Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain,” Revista de Neurología, vol. 40, no. 12, pp. 705–710, 2005. View at Google Scholar
  96. R. Sanchez-De la Rosa, E. Sabater, and M. A. Casado, “Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain,” Revista de Neurología, vol. 53, no. 3, pp. 129–138, 2011. View at Google Scholar
  97. N. Scolding, “The multiple sclerosis risk sharing scheme,” British Medical Journal, vol. 340, p. c2882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Stock and R. Horowski, “A short history of beta-interferon therapy of multiple sclerosis,” Medizinische Klinik, vol. 96, supplement 1, pp. 3–9, 2001. View at Google Scholar · View at Scopus
  99. P. Tappenden, J. B. Chilcott, S. Eggington, J. Oakley, and C. McCabe, “Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis,” Health Technology Assessment, vol. 8, no. 27, pp. 1–78, 2004. View at Google Scholar · View at Scopus
  100. P. Tappenden, C. McCabe, J. Chilcott et al., “Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population,” Value in Health, vol. 12, no. 5, pp. 657–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Tappenden, R. Saccardi, C. Confavreux et al., “Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis,” Bone Marrow Transplantation, vol. 45, no. 6, pp. 1014–1021, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. A. J. Thompson, “Inequality in the availability of expensive treatments,” Journal of the Royal College of Physicians of London, vol. 33, no. 5, pp. 448–449, 1999. View at Google Scholar
  103. K. H. Tolley and D. K. Whynes, “Interferon-β in multiple sclerosis. Can we control its costs?” PharmacoEconomics, vol. 11, no. 3, pp. 210–215, 1997. View at Google Scholar · View at Scopus
  104. D. R. Touchette, T. L. Durgin, L. A. Wanke, and D. E. Goodkin, “A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis,” Clinical Therapeutics, vol. 25, no. 2, pp. 611–634, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Walley, “Neuropsychotherapeutics in the UK: what Has Been the Impact of NICE on Prescribing?” CNS Drugs, vol. 18, no. 1, pp. 1–12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Pan, J. W. Goh, G. Cutter, W. Su, D. Pleimes, and C. Wang, “Long-term cost-effectiveness model of interferon Beta-1b in the early treatment of multiple sclerosis in the United States,” Clinical Therapeutics, vol. 34, no. 9, pp. 1966–1976, 2012. View at Google Scholar
  107. J. P. Caloyeras, B. Zhang, C. Wang et al., “Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis,” Clinical Therapeutics, vol. 34, no. 5, pp. 1132–1144, 2012. View at Google Scholar
  108. G. Kobelt, B. Texier-Richard, and P. Lindgren, “The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions,” Multiple Sclerosis, vol. 15, no. 6, pp. 741–751, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. P. Perini, M. Calabrese, M. Tiberio, F. Ranzato, L. Battistin, and P. Gallo, “Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study,” Journal of Neurology, vol. 253, no. 8, pp. 1034–1040, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. D. S. Goodin, E. M. Frohman, G. P. Garmany et al., “Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines,” Neurology, vol. 58, no. 2, pp. 169–178, 2002. View at Google Scholar · View at Scopus
  111. National Collaborating Centre for Chronic Conditions, “Multiple sclerosis: management of multiple sclerosis in primary and secondary care,” Tech. Rep., National Institue for Clinical Excellence, London, UK, 2003. View at Google Scholar
  112. M. C. Weinstein, B. O'Brien, J. Hornberger et al., “Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies,” Value in Health, vol. 6, no. 1, pp. 9–17, 2003. View at Publisher · View at Google Scholar · View at Scopus